Claims for Patent: 7,790,398

Summary for Patent: 7,790,398

Title:	Method for determining effective parathormone activity in a sample
Abstract:	Method for determining the active parathyroid hormone content in a sample, wherein the component of parathyroid hormone polypeptide chains which are oxidized at one or more sites near the PTH receptor binding structure having the amino acids 15 to 22 are specifically excluded from the content determination. Oxidation of the parathyroid hormone occurs in particular in dialysis patients, their blood plasma being exposed to an oxidation stress in the dialysis. The invention is based on the use of antibodies which bind specific conformation epitopes of the oxidised or reduced parathyroid hormone and its fragments. Further, there is provided a test system for the quantitative determination of parathyroid hormone and active fragments hereof in a sample.
Inventor(s):	Armbruster; Franz Paul (67240 Bobenheim-Roxheim, DE), Roth; Heinz-Juergen (69126 Heidelberg, DE), Schmidt-Gayk; Heinrich (69126 Heidelberg, DE)
Assignee:
Application Number:	10/473,975
Patent Claims:	1. A method of determining the concentration of biologically active human parathyroid hormone in a physiological sample, wherein said method comprises: contacting a first antibody with a sample, wherein said sample comprises a body fluid, wherein the first antibody specifically recognizes human parathyroid hormone polypeptide chains and fragments thereof which comprise oxidized residues at methionine 8 and/or methionine 18; contacting a second antibody with the sample, wherein said second antibody specifically recognizes an epitope formed by the N-terminal amino acids 1 to 3 of the human parathyroid hormone polypeptide chains; and contacting a third antibody with the sample, where the third antibody specifically recognizes an epitope within amino acids 15 to 22 of the human parathyroid hormone polypeptide chains, whereby human parathyroid hormone comprising oxidized methionine residues are precluded from detection by binding of the first antibody, which blocks the second antibody and/or third antibody from binding to oxidized parathyroid hormone polypeptide chains and fragments thereof, thereby determining the concentration of biologically active human parathyroid hormone recognized by the second and third antibodies. 2. The method according to claim 1, wherein the first antibody masks oxidized parathyroid hormone and its fragments, such that exclusively reduced, biologically active parathyroid hormone and its fragments are detected. 3. The method according to claim 1, wherein the method further comprises adding from 0.05 to 0.1 weight % of a mild detergent to the sample. 4. The method according to claim 1, wherein the first antibody is a monoclonal antibody. 5. A method of determining the concentration of reduced biologically active human parathyroid hormone (hPTH) in a physiological sample, wherein said method comprises: dividing a sample into two sample aliquots; contacting a first antibody with a first sample aliquot wherein the first antibody specifically recognizes hPTH polypeptide chains and fragments thereof which comprise oxidized residues methionine 8 and/or methionine 18, and determining a concentration of oxidized human parathyroid in the sample aliquot; contacting a second antibody with a second sample aliquot, wherein the second antibody specifically recognizes an epitope formed by N-terminal amino acids 1 to 3 of hPTH polypeptide chains; contacting a third antibody with the second sample aliquot, wherein said third antibody specifically recognizes an epitope within amino acids 15 to 22 of human parathyroid hormone polypeptide chains; determining the total concentration of oxidized and reduced hPTH in the second sample aliquot; and calculating the concentration of reduced, biologically active hPTH in the second sample from the total oxidized and reduced concentration of hPTH in the second sample and the concentration of oxidized hPTH in the first sample. 6. The method according to any one of claims 1-4, wherein the second antibody or the third antibody comprise a detectable marker, wherein said marker is selected from the group consisting of: a fluorescing group a chemiluminescing group and an enzyme for catalysis of a detection reaction. 7. The method according to any one of claims 1-4, wherein the second antibody or the third antibody is biotinylated. 8. The method according to any one of claims 1-4, wherein the third antibody is a monoclonal antibody, and wherein the third antibody comprises a ruthenium complex, and wherein the third antibody recognizes an epitope in the region of the amino acids 15 to 22 of human parathyroid hormone. 9. A method of determining the concentration of biologically active human parathyroid hormone in a physiological sample, wherein said method comprises: providing a sample, wherein said sample comprises a body fluid; contacting the sample with a first antibody, wherein the first antibody specifically recognizes human parathyroid hormone polypeptide chains which are oxidized at methionine 8 and/or methionine 18; determining the amount of intact parathyroid hormone peptide chains and N-terminally intact fragments thereof in said sample by sandwich immunoassay, wherein said sandwich immunoassay comprises a second antibody and a third antibody, and wherein one of the second antibody or third antibody specifically binds to the receptor-binding site within amino acids 15 to 22 of the human parathyroid hormone polypeptide chain, and the other one of the second antibody or third antibody binds to either an epitope formed by amino acids 1 to 3 of the human parathyroid hormone or to the middle or C-terminal section of the human parathyroid hormone polypeptide chain, whereby human parathyroid hormone comprising oxidized methionine residues are precluded from detection by binding of the first antibody, which blocks the second antibody and/or third antibody from binding to oxidized parathyroid hormone polypeptide chains and fragments thereof, thereby determining the concentration of biologically active human parathyroid hormone. 10. The method of claim 9, wherein the respective second or third antibody which binds to the middle or C-terminal section of the human parathyroid hormone polypeptide chain recognizes an epitope within amino acids 53 to 68 of the human parathyroid hormone polypeptide chain. 11. The method of claim 9, wherein the respective second or third antibody which binds to the middle or C-terminal section of the human parathyroid hormone polypeptide chain recognizes an epitope within amino acids 53 to 84 of the human parathyroid hormone polypeptide chain.

Details for Patent 7,790,398

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2021-04-03